Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies worldwide. The Company's core business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. The company was founded in 1989 and is based in Irvine, California.
ReportsnReports.com the exclusive leading provider of market research reports published research report on “Global Respiratory Monitoring Equipment Market Research Report 2020”. The Global Respiratory Monitoring Equipment Market Report 2020 is a professional and in-depth study on the current state of the
ReportsnReports.com the exclusive leading provider of market research reports published research report on “Global Wearable Patient Monitor Market Research Report 2020”. The Global Wearable Patient Monitor Market Report 2020 is a professional and in-depth study on the current state of the
Masimo Corp. provided lower-than-projected profit guidance for 2021, while the medical instruments manufacturer expects adjusted earnings for last year to exceed the initial forecast of $3.46 per share. Masimo (MASI) is scheduled to report its 2020 financial results on Feb. 23. Analysts expect the company to report adjusted earnings of $3.49 per share in 2020. Further, the company forecasted to generate product revenues in the range of $1.139 billion to $1.144 billion, representing year-over-year growth of 21.6% to 22.2%. The company expects shipments of noninvasive technology boards and instruments of about 472,000 in 2020. As for 2021, the company sees adjusted earnings of $3.
Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds sold 10,000 shares of Masimo stock in a transaction that occurred on Monday, January 11th. The stock was sold at an average price of $279.74, for a total transaction of $2,797,400.00. Following the completion of the transaction, the director now owns 14,300 shares in the company, valued at […]